No products in the cart.
Tirzepatide Injection MOUNJARO wholesale – Multi-Dose Research-Use Only
$1.00
Tirzepatide Injection (MOUNJARO) contains 40mg (4 doses of 10mg/0.6ml) per vial. Manufactured by Eli Lilly Italia S.p.A. Approved in China (HJ20255004). Intended for laboratory research only. Wholesale and retail supported.?For wholesale prices, other specifications and uses, please consult our staff?
Description
Tirzepatide is a novel dual GIP and GLP-1 receptor agonist designed to regulate insulin secretion, appetite control, and glucose metabolism. It has gained attention as a next-generation metabolic compound used in obesity and type 2 diabetes research.
Mufengda (MOUNJARO) is a multi-dose injectable formulation, offering 4 x 10mg doses (total 40mg in 2.4ml) per vial. This structure makes it highly adaptable for varied research models in metabolic regulation, endocrinology, and obesity-related studies.
?? This product is strictly for laboratory research use only. Not approved for clinical or veterinary application.
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | Tirzepatide Injection (Mufengda/MOUNJARO) |
| Generic Name | Tirzepatide |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C???H???N??O?? |
| Molecular Weight | ~4813 Da |
| Dosage Form | Injection |
| Strength | 40mg per 2.4ml (4 x 10mg/0.6ml doses) |
| Quantity | 1 vial per box |
| Approval Number | HJ20255004 (China NMPA) |
| Product Code | 86978403001637 |
| Manufacturer | Eli Lilly Italia S.p.A. |
| Storage Conditions | Refrigerate at 2–8°C; do not freeze |
| Intended Use | Laboratory research only |
Mechanism & Research Applications
Tirzepatide mimics the action of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual receptor agonism enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces food intake.
It is actively applied in research related to:
Obesity and metabolic syndrome models
Type 2 diabetes mellitus (T2DM) mechanisms
Insulin resistance and glycemic control studies
Appetite suppression and gut-brain signaling
GLP-1 and GIP pathway pharmacodynamics
Observed Effects in Research Models
In preclinical and in vitro models, tirzepatide has demonstrated:
Enhanced glucose-dependent insulin secretion
Decreased food intake and body weight
Lowered HbA1c and fasting plasma glucose
Synergistic effects with other metabolic regulators
These properties make it ideal for endocrinology, nutrient metabolism, and anti-obesity drug development studies.
Safety & Handling
Research Use Only: Not for human, diagnostic, or veterinary use
Storage: 2–8°C. Do not freeze. Use under sterile lab conditions
PPE: Gloves, safety glasses, and lab coat recommended
Disposal: Follow institutional biohazard and chemical disposal protocols
Research Use Disclaimer
This product is intended strictly for laboratory research use only. It is not approved for clinical, therapeutic, diagnostic, or veterinary purposes. Handle with care in a certified research environment following institutional safety protocols.
Additional information
| Weight | 1 kg |
|---|---|
| Dimensions | 26 × 23 × 26 cm |
1 review for Tirzepatide Injection MOUNJARO wholesale – Multi-Dose Research-Use Only
Q1: Is Tirzepatide Injection (MOUNJARO) approved for human use?
No. This version is strictly designated for laboratory research use only. It is not authorized for therapeutic or diagnostic application.
Q2: How is the dosage structured in the vial?
Each vial contains 2.4ml with 40mg tirzepatide, designed to deliver four 10mg doses (0.6ml each) for flexible experimental dosing.
Q3: What is the primary mechanism studied with tirzepatide?
Tirzepatide acts as a dual GIP and GLP-1 receptor agonist, useful in researching glycemic regulation, energy balance, and appetite suppression pathways.
Q4: Can I order this product in bulk?
Yes. Both retail and wholesale orders are supported, and we provide international shipping with full documentation.
Q5: What makes Mufengda's formulation reliable for research?
The product from Eli Lilly Italia S.p.A., approved under HJ20255004, offers consistent quality and accurate dosing—ideal for labs researching tirzepatide injection, GLP-1 analogues, or anti-obesity mechanisms.
Related products
Voglibose Tablets (Litanging) 0.2mg – Factory low price wholesale
Litanging Voglibose Tablets contain 0.2mg of voglibose per tablet, supplied in 60-tablet boxes. Produced by Shijiazhuang Huaxin Pharmaceutical Co., Ltd. NMPA-approved under H20163123. Intended for experimental/laboratory use only.?For wholesale prices, other specifications and uses, please consult our staff?
$3.00Pioglitazone Hydrochloride Tablets (Aiting) 15mg – For Laboratory Research Use Only
Pioglitazone Hydrochloride Tablets (Aiting) contain 15mg of active compound per tablet. Supplied as 14 tablets (2 blister packs). Manufactured by Beijing Taiyang Pharmaceutical under NMPA approval H20040267. Suitable for lab research in glucose metabolism and insulin signaling.?For wholesale prices, other specifications and uses, please consult our staff?
$1.20Epalrestat Tablets 50mg – For Laboratory Research Use Only
Epalrestat Tablets provide 50mg of active compound per tablet. Manufactured by Hebei Ruisen Pharmaceutical Co., Ltd. Approved under H20253680. Intended strictly for laboratory research use only. Supports both bulk and individual orders.?For wholesale prices, other specifications and uses, please consult our staff?
$2.00Liraglutide Injection
Liraglutide 18mg in a 3ml prefilled pen, branded Tonboli, produced by Tonghua Dongbao Pharmaceutical Co., Ltd. Approved under NMPA S20230066, ideal for GLP-1 receptor agonist research, metabolic studies, and diabetes modelling. $2.00
Ahmet –
The package is intact, thank you, I will contact you if I need it